Company Overview of Sandoz Inc.
Sandoz Inc. develops, manufactures, markets, and distributes generic pharmaceutical products. Its therapeutic drug categories include anti-infectives, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agents, oncology therapies, respiratory therapies, alimentary tract and metabolism, blood and blood-forming organs, and antineoplastic and immunomodulating agents. The company provides oral solid generics to advanced application forms, such as transdermal patches and implants; and complex products, such as follow-on biologics (biosimilars), injectables, and inhalables. It sells its products to small and large retailers, wholesalers, hospitals, prescription b...
100 College Road West
Princeton, NJ 08540
Founded in 1946
Key Executives for Sandoz Inc.
President and Head of North America
Chief Financial Officer, Head of Finance - North America and Vice President
President of Oriel Therapeutics
Vice President of Legal, IP & Compliance and General Counsel of NA
Head of Global Development Biopharmaceuticals & Oncology Injectables
Compensation as of Fiscal Year 2014.
Sandoz Inc. Key Developments
Sandoz Wins $67.18 Million Federal Contract
Apr 24 15
Sandoz won a $67,179,359 federal contract from the Defense Logistics Agency, Philadelphia, for potassium chloride.
Sandoz Inc. Wins $1.97 Million Federal Contract
Mar 3 15
Sandoz Inc. won a $1,973,552.50 federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center, Hines, Illinois, for medical, dental and veterinary equipment and supplies.
Sandoz Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reports Impairment Charges
Jan 27 15
Sandoz announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales were USD 2.5 billion against USD 2.41 billion a year ago. Operating income was USD 290 million against USD 276 million a year ago. Core operating income was USD 416 million against USD 373 million a year ago.
For the full year, the company reported net sales were USD 9.56 billion against USD 9.16 billion a year ago. Operating income was USD 1.09 billion against USD 1.03 billion a year ago. Core operating income was USD 1.57 billion against USD 1.54 billion a year ago. Operating income increased by 6%, benefiting from strong operating performance and unrepeated prior-year legal settlements.
The company reported total impairment charges of USD 18 million for the fourth quarter of 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|